Enoxaparin (Clexane) Dosing for NSTEMI Based on eGFR
For NSTEMI patients, administer enoxaparin 1 mg/kg subcutaneously every 12 hours as standard therapy, but reduce to 1 mg/kg once daily when creatinine clearance falls below 30 mL/min. 1, 2
Standard Dosing Algorithm
For Patients with CrCl ≥30 mL/min:
- Administer 1 mg/kg subcutaneously every 12 hours as the standard regimen 1, 2
- An optional 30 mg IV loading dose may be given in selected patients, though this increases bleeding risk 1
- Do not exceed 1.05 mg/kg per administration, as higher doses are linked to increased bleeding rates 1
For Elderly Patients (≥75 years):
- Omit the IV bolus entirely 1, 2
- Reduce the maintenance dose to 0.75 mg/kg subcutaneously every 12 hours 1, 2
For Severe Renal Impairment (CrCl <30 mL/min):
- Reduce enoxaparin to 1 mg/kg subcutaneously once daily (approximately 50% of the total daily dose) 1, 2
- This once-daily dosing applies regardless of age 2
Critical Renal Dosing Considerations
The CrCl threshold of 30 mL/min is the key decision point for dose adjustment. 1, 2 Research demonstrates that enoxaparin clearance decreases by 31% in moderate renal impairment and 44% in severe renal impairment, leading to significant drug accumulation with standard dosing 3. The once-daily regimen in severe renal impairment prevents this accumulation while maintaining therapeutic anti-Xa levels 4.
Alternative for Severe Renal Impairment:
- Consider switching to unfractionated heparin (UFH) in patients with CrCl <30 mL/min, as UFH does not accumulate in renal failure and allows tighter titration 1
- UFH regimen: 60 IU/kg IV bolus (max 4000 IU) followed by 12 IU/kg/h infusion (max 1000 IU/h), adjusted to maintain aPTT 1.5–2.0 × control 1
Duration of Therapy
- Continue enoxaparin until PCI is performed or for the duration of hospitalization (minimum 48 hours, up to 8 days) 1, 2
- Premature discontinuation is associated with rebound thrombin activity and reinfarction risk, with greatest risk in the first 4–8 hours after stopping 2
Monitoring
- Routine anti-Xa level monitoring is not required for most patients receiving therapeutic enoxaparin 1
- Anti-Xa monitoring may be considered in severe renal impairment if there is concern about accumulation, though the once-daily dosing regimen has been validated as safe 4
Common Pitfalls to Avoid
- Do not use arbitrary dose reductions in moderate renal impairment (CrCl 30–50 mL/min), as this increases ischemic event risk without clear bleeding benefit 5
- Do not "stack" enoxaparin with UFH, as this significantly increases bleeding risk 6
- Do not give the IV bolus to patients ≥75 years, even with normal renal function 1, 2
- Remember that the dose adjustment threshold is based on creatinine clearance (CrCl), not eGFR, though these are often used interchangeably in clinical practice 1, 2